Ксалуритамиг
XaluritamigМНН
Rec. INN (наименование, зарегистрированное ВОЗ)
CAS
2559056-68-5
Химическое название
immunoglobulin G1-scFv-CH/G1-kappa, anti-[Homo sapiens STEAP1 (STEAP family member 1, six transmembrane epithelial antigen of the prostate 1, STEAP1 metalloreductase) and anti-[Homo sapiens CD3, bispecific, trivalent;
gamma1 heavy chain VH-CH1-scFv-CH2-CH3, bispecific (1-723) [VH anti-STEAP1 (Homo sapiens IGHV1-3*01 (80.6%) -(IGHD) -IGHJ4*01 (86.7%), CDR-IMGT [8.8.14] (26-33.51-58.97-110))] (1-121) -Homo sapiens IGHG1*03v CH1-h (CH1 G1m3>G1m17, R120>K (218) (122-219), hinge 1-5 (220-224)) (122-224) -10-mer bis(tetraglycyl-seryl) linker (225-234) -scFv anti-CD3 [VH (Homo sapiens IGHV3-73*01 (87.0%) -(IGHD) -IGHJ6*01 (90.9%), CDR-IMGT [8.8.16] (260-267.285-294.333-348)) (235-359) -20-mer tetra(glycyl-lysyl-prolyl-glycyl-seryl) (360-379) -V-LAMBDA (IGLV7-46*01 (76.8%) -(IGHD) -IGHJ3*02 (100%), CDR-IMGT [9.3.9] (405-413.431-433.470-478)) (380-488)] (235-488) -10-mer bis(tetraglycyl-seryl) linker (489-498) -IGHG1*03v h-CH2-CH3 (hinge 7-15 (499-507), CH2 G1v30 G84.4 (92.7%), ELLG>PVA (G2-like) (510,511,512), S29>K (543), R83>C (568), N84.4>G (573), V85>C (578) (508-616), CH3 nG1m1 (98.1%) E12 (632), E13>Q (633), M14 (634), S20>K (640) (617-721), CHS (722-723)) (499-723)], (224-213')-disulfide with kappa light chain anti-STEAP1 Homo sapiens (1'-213') [V-KAPPA (Homo sapiens IGKV3-11*01 (86.3%) -IGKJ2*01 (100%), CDR-IMGT [5.3.9] (27-31.49-51.88-96)) (1'-106') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (152), V101 (190) (107'-213')];
gamma1 heavy chain anti-STEAP1 (1''-450'') [VH (Homo sapiens IGHV1-3*01 (80.6%) -(IGHD) -IGHJ4*01 (86.7%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1''-121'') -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 G84.4 (CH1 N114>D (212), R120>K (218) (122''-219''), hinge 1-15 (220''-234''), CH2 (91.8%) ELLG>PVA (G2-like) (237,238,239), S29>K (270), R83>C (295), Q84.2>E (298), N84.4>G (300), V85>C (305) (235''-343''), CH3 (95.2%) E12 (359), M14 (361), L24>D (371), K26>S (373), N44>D (387), Q97>E (421), N100>D (424) (344''-448''), CHS (449''-450''))], (224''-213''')-disulfide with kappa light chain anti-STEAP1 Homo sapiens (1'''-213''') [V-KAPPA (Homo sapiens sapiens IGKV3-11*01 (86.3%) -IGKJ2*01 (100%), CDR-IMGT [5.3.9] (27-31.49-51.89-96)) (1'''-106''') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (152), V101 (190) (107'''-213''')];
dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, non-glycosylated
gamma1 heavy chain VH-CH1-scFv-CH2-CH3, bispecific (1-723) [VH anti-STEAP1 (Homo sapiens IGHV1-3*01 (80.6%) -(IGHD) -IGHJ4*01 (86.7%), CDR-IMGT [8.8.14] (26-33.51-58.97-110))] (1-121) -Homo sapiens IGHG1*03v CH1-h (CH1 G1m3>G1m17, R120>K (218) (122-219), hinge 1-5 (220-224)) (122-224) -10-mer bis(tetraglycyl-seryl) linker (225-234) -scFv anti-CD3 [VH (Homo sapiens IGHV3-73*01 (87.0%) -(IGHD) -IGHJ6*01 (90.9%), CDR-IMGT [8.8.16] (260-267.285-294.333-348)) (235-359) -20-mer tetra(glycyl-lysyl-prolyl-glycyl-seryl) (360-379) -V-LAMBDA (IGLV7-46*01 (76.8%) -(IGHD) -IGHJ3*02 (100%), CDR-IMGT [9.3.9] (405-413.431-433.470-478)) (380-488)] (235-488) -10-mer bis(tetraglycyl-seryl) linker (489-498) -IGHG1*03v h-CH2-CH3 (hinge 7-15 (499-507), CH2 G1v30 G84.4 (92.7%), ELLG>PVA (G2-like) (510,511,512), S29>K (543), R83>C (568), N84.4>G (573), V85>C (578) (508-616), CH3 nG1m1 (98.1%) E12 (632), E13>Q (633), M14 (634), S20>K (640) (617-721), CHS (722-723)) (499-723)], (224-213')-disulfide with kappa light chain anti-STEAP1 Homo sapiens (1'-213') [V-KAPPA (Homo sapiens IGKV3-11*01 (86.3%) -IGKJ2*01 (100%), CDR-IMGT [5.3.9] (27-31.49-51.88-96)) (1'-106') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (152), V101 (190) (107'-213')];
gamma1 heavy chain anti-STEAP1 (1''-450'') [VH (Homo sapiens IGHV1-3*01 (80.6%) -(IGHD) -IGHJ4*01 (86.7%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1''-121'') -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 G84.4 (CH1 N114>D (212), R120>K (218) (122''-219''), hinge 1-15 (220''-234''), CH2 (91.8%) ELLG>PVA (G2-like) (237,238,239), S29>K (270), R83>C (295), Q84.2>E (298), N84.4>G (300), V85>C (305) (235''-343''), CH3 (95.2%) E12 (359), M14 (361), L24>D (371), K26>S (373), N44>D (387), Q97>E (421), N100>D (424) (344''-448''), CHS (449''-450''))], (224''-213''')-disulfide with kappa light chain anti-STEAP1 Homo sapiens (1'''-213''') [V-KAPPA (Homo sapiens sapiens IGKV3-11*01 (86.3%) -IGKJ2*01 (100%), CDR-IMGT [5.3.9] (27-31.49-51.89-96)) (1'''-106''') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (152), V101 (190) (107'''-213''')];
dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, non-glycosylated
Структура
Иностранные названия
- Xaluritamigum (латинское)
- Xaluritamig (английское)
- Xaluritamig (немецкое)
- Xaluritamig (французское)
- Xaluritamig (испанское)
Подробнее по теме
Узнайте дополнительные сведения о действующем веществе Ксалуритамиг: